Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Shares Issued (2017 - 2025)

Seres Therapeutics (MCRB) has disclosed Shares Issued for 9 consecutive years, with $215000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 121.56% to $215000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $230000.0 through Dec 2025, down 91.61% year-over-year, with the annual reading at $230000.0 for FY2025, 52.77% down from the prior year.
  • Shares Issued hit $215000.0 in Q4 2025 for Seres Therapeutics, up from -$169000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $95.9 million in Q4 2022 to a low of -$997000.0 in Q4 2024.
  • Historically, Shares Issued has averaged $6.7 million across 5 years, with a median of $236000.0 in 2022.
  • Biggest five-year swings in Shares Issued: skyrocketed 11696.74% in 2022 and later crashed 104.99% in 2025.
  • Year by year, Shares Issued stood at -$827000.0 in 2021, then surged by 11696.74% to $95.9 million in 2022, then plummeted by 92.19% to $7.5 million in 2023, then tumbled by 113.31% to -$997000.0 in 2024, then skyrocketed by 121.56% to $215000.0 in 2025.
  • Business Quant data shows Shares Issued for MCRB at $215000.0 in Q4 2025, -$169000.0 in Q3 2025, and $184000.0 in Q1 2025.